Noah Hahn
Johns Hopkins University · Hoosier Cancer Research Network · Hoosier Oncology Group, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Noah Hahn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02845323 · Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Urothelial Carcinoma, Bladder Cancer · principal investigator
- Ph2NCT01780545 · Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder CancerNoah Hahn, M.D. · completed · Bladder Cancer, Urothelial Carcinoma · study chair
- Ph2NCT01732107 · Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expressionNoah Hahn, M.D. · terminated · Bladder Cancer · study chair
- Ph2NCT00860158 · Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate CancerNoah Hahn, M.D. · terminated · Prostate Cancer · study chair
- Ph2NCT00859339 · Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCCNoah Hahn, M.D. · terminated · Transitional Cell Carcinoma of the Bladder · study chair
- N/ANCT00706641 · Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the BladderHoosier Cancer Research Network · completed · Transitional Cell Carcinoma of the Bladder · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)R01CA235681 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2019 to 2024 · $243,567 awarded in 2024Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:29 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.N Engl J Med · 20152,395 citationsRCR 78.3
- 1,070 citationsRCR 34.1
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.J Clin Oncol · 2018877 citationsRCR 32.8
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol · 2017726 citationsRCR 22.6
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.J Clin Oncol · 2019549 citationsRCR 20.8
- 234 citationsRCR 9.1
- Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.J Clin Oncol · 2011165 citationsRCR 4.1
- Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.J Clin Oncol · 2012154 citationsRCR 3.6
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.J Clin Oncol · 2020118 citationsRCR 4.0
- 116 citationsRCR 5.2